$0.80
+0.03 (+4.32%)
Open$0.75
Previous Close$0.76
Day High$0.80
Day Low$0.75
52W High$2.57
52W Low$0.72
Volume—
Avg Volume379.5K
Market Cap50.45M
P/E Ratio—
EPS$-0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,330.5% upside
Current
$0.80
$0.80
Target
$11.39
$11.39
$7.11
$11.39 avg
$14.81
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.04M | 5.52M | 16.16M |
| Net Income | -63,358,185 | -62,415,024 | -2,032,977 |
| Profit Margin | -1,256.8% | -1,194.0% | -12.6% |
| EBITDA | -64,910,615 | -67,496,808 | -2,828,117 |
| Free Cash Flow | — | — | -1,769,464 |
| Rev Growth | -8.6% | -8.6% | -2.0% |
| Debt/Equity | 0.26 | 0.26 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |